.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually selected Eli Lilly (NYSE: LLY) as its best biopharma choice for 2025 as well as measured yet another nine titles in the area as over weight. The assets financial institution stated in a details that it continues to feel “diabesity is actually readied to come to be.